RDMD is a healthcare technology company dedicated to accelerating drug research for patients with rare diseases.
RDMD's mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.
RDMD was founded in 2017 by Onno Faber, alongside with Nancy Yu. The company is headquartered in San Francisco, California.
RDMD has developed a technology platform that generates FDA-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in drug research online and benefit from their own medical data.
RDMD is the only patient-centered, regulatory-grade, real world evidence platform focused on the unique and growing challenges in rare disease drug development.
RDMD is backed by Spark Capital, Lux Capital, Village Global, Garuda Ventures, Maveron Capital and others. The company is raised $14M in a Series A round on Apr 16, 2020. This brings RDMD's total funding to $17.1M to date.